Study Stopped
Subjects not entered into electronic database due to current construct of database and associated privacy legislations within Alberta.
A National Program for Severe Asthma: The Canadian Severe Asthma Network
CSAN
1 other identifier
observational
N/A
1 country
1
Brief Summary
The Canadian Severe Asthma Network (CSAN) was developed to gain a better understanding of the clinical, environmental, socio-economic, work-related, and biological characteristics of severe asthmatics (SA) that may account for poor response to clinically available therapies for asthma. This network of clinical and basic researchers will be a means by which Canadian investigators can develop and conduct research in this small patient group, which could lead to better clinical management of SA. Patient information will be entered into the CSAN database (created by PI Dr. Vethanayagam in connection with Mr. Jack Yeung) and will help researchers and doctors from multiple hospitals and universities across Canada to understand this subpopulation of asthmatics better. It will help to answer questions regarding SA epidemiology, asthma education, inflammatory monitoring, risks of near fatal asthma (NFA), symptom perception, changes in lung structure and function, co-morbidities, and the effectiveness of developing regional severe asthma clinics. Two of the early projects the investigators will be working on are psychosocial co-morbidities in asthma and medication coverage related to asthma. There will also be biobanking of sputum samples and/or bronchoscopy samples (such as BALs \& lung washings) that are being obtained for clinical purposes. Also, for those consented for biobanking blood and urine will be collected, separate from clinical care, and stored in the biobank. The Canadian Biosample Repository (CBSR) will be storing our biobanked samples. The investigators will be following the CBSR policies for storage and security. Tissue research will be conducted in the future, and separate ethics approval will be obtained for each project.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
Started Jun 2010
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 5, 2009
CompletedFirst Posted
Study publicly available on registry
August 7, 2009
CompletedStudy Start
First participant enrolled
June 1, 2010
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2012
CompletedStudy Completion
Last participant's last visit for all outcomes
August 1, 2012
CompletedAugust 24, 2012
August 1, 2012
2.2 years
August 5, 2009
August 23, 2012
Conditions
Study Arms (2)
Severe asthmatics
Main study group
Mild-moderate asthmatics
Control group
Eligibility Criteria
Severe asthmatics as the primary study group, mild-moderate asthmatics as the control group
You may qualify if:
- Adults (18 and older) with physiologically confirmed SA or mild-moderate asthma and followed by an asthma specialist for at least 6 months.
- Must agree to have regular clinic visits (minimum 3-4 per year for SA, 1-2 for mild-moderate asthma).
- Must have good compliance with medications Patients with asthma and COPD.
You may not qualify if:
- Malignancy and other significant medical conditions that will impact follow up within this program.
- Those less than 18 years of age.
- Concomitant interstitial lung disease, sarcoidosis, other significant lung disease.
- Those who have had a transplant.
- Significant travel with work.
- Unable to make appointments (every three to six months over 2 years).
- Those residing in another country or planned absence for more than one month.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
University of Alberta Hospital
Edmonton, Alberta, T6G 2B7, Canada
Related Links
Biospecimen
If consented to by the patient, extra clinical specimens - sputum plugs, sputum supernatant, blood and urine will be stored. If patients undergo a clinical bronchoscopy, mucosal biopsies x 2 and bronchoalveolar lavage will be stored.
Study Officials
- PRINCIPAL INVESTIGATOR
Dilini Vethanayagam, MD
University of Alberta
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Associate Professor, Medicine (Pulmonary)
Study Record Dates
First Submitted
August 5, 2009
First Posted
August 7, 2009
Study Start
June 1, 2010
Primary Completion
August 1, 2012
Study Completion
August 1, 2012
Last Updated
August 24, 2012
Record last verified: 2012-08